Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Comprehensive clinical development programs being initiated for each investigational candidate
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
Star Health's convenient claims process, valued added offerings like free telemedicine consultations with expert doctors
The company has received five final approvals
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
ABDM Microsites Mobile Application for field officers and ABDM Microsites Dashboard launched for effective on-ground implementation and monitoring
Subscribe To Our Newsletter & Stay Updated